JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Închisă

SectorSănătate

198.07 -0.35

Rezumat

Modificarea prețului

24h

Curent

Minim

198

Maxim

198.64

Indicatori cheie

By Trading Economics

Venit

1.3B

1.3B

Vânzări

2.1B

15B

P/E

Medie Sector

92.578

34.393

EPS

2.97

Randament dividend

3.31

Marjă de profit

9.66

Angajați

55,000

EBITDA

-4.3B

117M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+9.3% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.31%

2.54%

Următoarele câștiguri

29 oct. 2025

Data viitoare de dividende

15 aug. 2025

Următoarea dată ex-dividende

14 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

12B

348B

Deschiderea anterioară

198.42

Închiderea anterioară

198.07

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

AbbVie Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 iul. 2025, 12:46 UTC

Câștiguri

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30 iun. 2025, 13:02 UTC

Achiziții, Fuziuni, Preluări

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 apr. 2025, 13:57 UTC

Câștiguri

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 apr. 2025, 12:52 UTC

Câștiguri

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31 iul. 2025, 12:08 UTC

Câștiguri

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31 iul. 2025, 11:46 UTC

Câștiguri

AbbVie Raises FY Outlook

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q Adj EPS $2.97 >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q EPS 52c >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q Rev $15.42B >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31 iul. 2025, 11:44 UTC

Câștiguri

AbbVie 2Q Net $938M >ABBV

30 iun. 2025, 12:47 UTC

Achiziții, Fuziuni, Preluări

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 iun. 2025, 12:33 UTC

Achiziții, Fuziuni, Preluări

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 iun. 2025, 12:33 UTC

Achiziții, Fuziuni, Preluări

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 iun. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 iun. 2025, 12:31 UTC

Achiziții, Fuziuni, Preluări

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 mai 2025, 09:30 UTC

Top știri

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 apr. 2025, 12:44 UTC

Câștiguri

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 apr. 2025, 09:33 UTC

Câștiguri

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr. 2025, 16:03 UTC

Câștiguri

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr. 2025, 14:00 UTC

Top știri
Câștiguri

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr. 2025, 12:24 UTC

Top știri
Câștiguri

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr. 2025, 12:03 UTC

Top știri
Câștiguri

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr. 2025, 11:43 UTC

Câștiguri

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 apr. 2025, 11:43 UTC

Câștiguri

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Comparație

Modificare preț

AbbVie Inc Așteptări

Obiectiv de preț

By TipRanks

9.3% sus

Prognoză pe 12 luni

Medie 216.47 USD  9.3%

Maxim 255 USD

Minim 170 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbbVie Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

11

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

180.37 / 195.54Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.